drugset / Trial / NCT00102141

Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women

NCT00102141

Phase 3 Completed 750 enrolled Bayer
RandomizedFactorialDouble-blindTreatment

Summary

The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension.

Timeline

Start
2004-04
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject 17ß-estradiol Unknown 1 mg Oral
Subject drospirenone Unknown 1 mg Oral
Subject drospirenone Unknown 2 mg Oral
Subject drospirenone Unknown 3 mg Oral